NRXP
NRx Pharmaceuticals, Inc. NASDAQ Listed Dec 4, 2017$3.06
Mkt Cap $52.9M
52w Low $1.62
64.9% of range
52w High $3.84
50d MA $2.31
200d MA $2.50
P/E (TTM)
-2.3x
EV/EBITDA
-3.2x
P/B
—
Debt/Equity
-0.0x
ROE
179.6%
P/FCF
-4.1x
RSI (14)
—
ATR (14)
—
Beta
1.83
50d MA
$2.31
200d MA
$2.50
Avg Volume
811.8K
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
1201 Orange Street · Wilmington, DE 19801 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.09 | 0.19 | +311.1% | 1.77 | +6.8% | +20.3% | +13.1% | -1.2% | -8.0% | -4.6% | — |
| Nov 14, 2025 | AMC | -0.11 | -0.18 | -63.6% | 2.49 | -8.0% | -15.3% | +8.1% | -6.6% | -4.7% | +4.9% | — |
| May 15, 2025 | AMC | -0.30 | -0.34 | -13.3% | 2.40 | -2.1% | +2.1% | -0.4% | +13.9% | -5.4% | +2.3% | — |
| Mar 14, 2025 | AMC | -0.20 | -0.30 | -50.0% | 2.35 | +0.0% | -12.8% | +7.3% | -0.9% | -5.0% | +0.5% | — |
| Nov 14, 2024 | AMC | -0.81 | -0.15 | +81.5% | 1.16 | +0.0% | +2.6% | +9.2% | -5.4% | -1.6% | +1.7% | — |
| Aug 14, 2024 | AMC | -0.81 | -0.75 | +7.4% | 1.86 | +3.8% | -6.5% | -0.6% | +0.0% | +5.8% | +3.8% | — |
| May 14, 2024 | AMC | -0.55 | -0.74 | -34.5% | 3.18 | +1.6% | +1.6% | +9.0% | +0.6% | +14.7% | -4.9% | — |
| Mar 29, 2024 | AMC | -0.70 | -0.50 | +28.6% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -1.10 | -0.70 | +36.4% | 3.36 | +4.2% | +4.2% | -7.1% | -6.8% | +2.0% | +0.6% | — |
| Aug 14, 2023 | AMC | -1.40 | -1.20 | +14.3% | 3.31 | -1.5% | +2.7% | -3.8% | +2.4% | -3.0% | -2.2% | — |
| May 16, 2023 | AMC | -1.50 | -1.30 | +13.3% | 6.46 | +0.6% | +5.3% | +0.0% | +5.9% | -4.9% | -2.9% | — |
| Mar 30, 2023 | AMC | -1.40 | -1.50 | -7.1% | 7.37 | -0.9% | -10.6% | -5.6% | -6.9% | -5.0% | +5.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $2.99 | +1.7% | +3.1% | -2.6% | -1.4% | +2.4% | +3.7% |
| Apr 27 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.94 | $2.99 | +1.7% | +3.1% | -2.6% | -1.4% | +2.4% | +3.7% |
| Apr 23 | D. Boral Capital | Maintains | Buy → Buy | — | $2.97 | $2.96 | -0.3% | -4.4% | +3.5% | +3.1% | -2.6% | -1.4% |
| Apr 20 | D. Boral Capital | Maintains | Buy → Buy | — | $2.55 | $2.55 | +0.0% | +25.5% | -7.8% | +0.7% | -4.4% | +3.5% |
| Mar 24 | BTIG | Maintains | Buy → Buy | — | $1.77 | $1.89 | +6.8% | +20.3% | +13.1% | -1.2% | -8.0% | -4.6% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $1.77 | $1.89 | +6.8% | +20.3% | +13.1% | -1.2% | -8.0% | -4.6% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $2.08 | $2.13 | +2.4% | -6.2% | -2.6% | -3.2% | +0.5% | -4.3% |
| Mar 16 | D. Boral Capital | Maintains | Buy → Buy | — | $1.86 | $1.95 | +4.8% | +11.8% | -6.2% | -2.6% | -3.2% | +0.5% |
| Mar 9 | D. Boral Capital | Maintains | Buy → Buy | — | $1.70 | $1.64 | -3.5% | +1.8% | +4.6% | +1.7% | -2.2% | +3.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.81 | $1.77 | -2.2% | -0.6% | +3.9% | -5.3% | -4.0% | +1.8% |
| Feb 18 | BTIG | Maintains | Buy → Buy | — | $1.80 | $1.79 | -0.6% | -1.1% | +3.4% | +0.0% | -4.3% | +7.4% |
| Feb 17 | D. Boral Capital | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | +0.0% | -1.1% | +3.4% | +0.0% | -4.3% |
| Jan 15 | BTIG | Maintains | Buy → Buy | — | $2.15 | $2.16 | +0.5% | +0.0% | +5.6% | -4.0% | +3.7% | +3.5% |
| Jan 5 | D. Boral Capital | Maintains | Buy → Buy | — | $2.62 | $2.62 | +0.0% | -8.0% | -0.8% | +2.5% | -4.9% | -4.7% |
| Jan 2 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.71 | $2.75 | +1.5% | -3.3% | -8.0% | -0.8% | +2.5% | -4.9% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $2.00 | +1.0% | +6.1% | +8.6% | -4.4% | +8.7% | +1.7% |
| Dec 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.27 | $2.27 | +0.0% | +6.2% | +1.2% | -3.3% | -4.2% | +4.0% |
| Dec 3 | BTIG | Maintains | Buy → Buy | — | $2.27 | $2.27 | +0.0% | +6.2% | +1.2% | -3.3% | -4.2% | +4.0% |
| Dec 2 | D. Boral Capital | Maintains | Buy → Buy | — | $2.39 | $2.45 | +2.5% | -5.0% | +6.2% | +1.2% | -3.3% | -4.2% |
| Nov 17 | D. Boral Capital | Maintains | Buy → Buy | — | $2.49 | $2.29 | -8.0% | -15.3% | +8.1% | -6.6% | -4.7% | +4.9% |
| Nov 10 | D. Boral Capital | Maintains | Buy → Buy | — | $2.45 | $2.51 | +2.4% | +3.7% | -2.0% | +6.0% | -1.9% | -3.9% |
| Oct 30 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.05 | $3.04 | -0.3% | -1.0% | +2.6% | -8.1% | -3.9% | -2.9% |
| Oct 21 | D. Boral Capital | Maintains | Buy → Buy | — | $3.31 | $3.39 | +2.4% | -3.0% | -1.9% | +1.6% | -1.6% | -0.3% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $3.18 | +0.3% | -4.1% | +4.6% | +4.1% | -3.0% | -1.9% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.30 | $3.31 | +0.3% | +1.2% | -0.3% | -1.8% | +2.4% | +9.6% |
| Sep 29 | D. Boral Capital | Maintains | Buy → Buy | — | $2.95 | $3.03 | +2.7% | +10.2% | +1.5% | +1.2% | -0.3% | -1.8% |
| Sep 25 | D. Boral Capital | Maintains | Buy → Buy | — | $2.99 | $2.99 | +0.0% | -2.7% | +1.4% | +10.2% | +1.5% | +1.2% |
| Sep 8 | D. Boral Capital | Maintains | Buy → Buy | — | $2.75 | $2.88 | +4.7% | +3.3% | +10.9% | -5.7% | -3.0% | -2.8% |
| Aug 22 | D. Boral Capital | Maintains | Buy → Buy | — | $2.53 | $2.59 | +2.4% | +4.3% | +1.9% | -2.2% | -1.9% | -2.3% |
| Aug 19 | D. Boral Capital | Maintains | Buy → Buy | — | $2.76 | $2.83 | +2.5% | -9.1% | +4.4% | -3.4% | +4.3% | +1.9% |
| Aug 11 | D. Boral Capital | Maintains | Buy → Buy | — | $2.52 | $2.60 | +3.2% | -7.9% | +3.0% | +5.9% | +5.5% | +8.2% |
| Aug 4 | D. Boral Capital | Maintains | Buy → Buy | — | $2.59 | $2.68 | +3.5% | +5.0% | -2.9% | -6.8% | +0.0% | +2.4% |
| Jun 23 | D. Boral Capital | Maintains | Buy → Buy | — | $3.26 | $3.19 | -2.1% | -4.9% | +3.9% | +1.6% | +7.0% | -2.3% |
| Jun 20 | D. Boral Capital | Maintains | Buy → Buy | — | $3.23 | $3.34 | +3.4% | +0.9% | -4.9% | +3.9% | +1.6% | +7.0% |
| Jun 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.94 | $3.02 | +2.7% | +11.2% | +12.2% | -0.5% | -4.7% | -1.1% |
| May 16 | D. Boral Capital | Maintains | Buy → Buy | — | $2.40 | $2.35 | -2.1% | +2.1% | -0.4% | +13.9% | -5.4% | +2.3% |
| Apr 30 | D. Boral Capital | Maintains | Buy → Buy | — | $2.06 | $2.08 | +1.0% | +2.9% | -1.9% | -1.4% | -1.0% | -5.4% |
| Apr 29 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.10 | $2.07 | -1.4% | -1.9% | +2.9% | -1.9% | -1.4% | -1.0% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $2.03 | $2.04 | +0.5% | +1.0% | -5.4% | +3.6% | -7.0% | -4.3% |
| Mar 24 | D. Boral Capital | Maintains | Buy → Buy | — | $2.08 | $2.20 | +5.8% | -0.5% | -2.9% | +3.0% | +0.0% | -1.9% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $2.18 | $2.18 | +0.0% | -5.0% | +0.5% | -0.5% | -2.9% | +3.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $2.18 | +0.0% | -5.0% | +0.5% | -0.5% | -2.9% | +3.0% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $2.35 | $2.35 | +0.0% | -12.8% | +7.3% | -0.9% | -5.0% | +0.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.09 | +1.0% | +13.5% | -12.8% | +7.3% | -0.9% | -5.0% |
| Jan 28 | D. Boral Capital | Maintains | Buy → Buy | — | $2.85 | $2.84 | -0.4% | +24.6% | -11.5% | -4.8% | +1.0% | -7.3% |
| Jan 6 | D. Boral Capital | Maintains | Buy → Buy | — | $2.69 | $2.92 | +8.6% | +30.5% | +32.8% | -19.3% | +29.0% | +1.2% |
| Jan 2 | D. Boral Capital | Maintains | Buy → Buy | — | $2.20 | $2.12 | -3.6% | +35.9% | -10.0% | +30.5% | +32.8% | -19.3% |
| Dec 31 | D. Boral Capital | Maintains | Buy → Buy | — | $1.53 | $1.55 | +1.3% | +43.8% | +35.9% | -10.0% | +30.5% | +32.8% |
| Dec 2 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.31 | $1.33 | +1.5% | +3.1% | -6.7% | -3.2% | -2.5% | +2.5% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.26 | $1.26 | +0.0% | +4.0% | -3.1% | +1.6% | +1.6% | +3.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
NRXP stockholders approved the company's independent auditor for fiscal 2025, indicating routine governance operations and no accounting firm controversy that could signal financial reporting risks.
Mar 24
8-K · 8.01
!! High
NRX Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
NRX Pharmaceuticals activated its S-3 shelf registration effective December 22, 2025, enabling the company to conduct future equity offerings and raise capital more efficiently.
Feb 17
8-K · 8.01
!! High
NRX Pharmaceuticals, Inc. -- 8-K 8.01: Material Event / Announcement
NRX Pharmaceuticals disclosed a material announcement via press release filing, though the specific details require reviewing the attached exhibit to assess investment implications.
Feb 17
8-K · 5.02
!!! Very High
Longeveron Inc. -- 8-K 5.02: Executive Change
Longeveron appointed Stephen H. Willard as Chief Executive Officer, signaling new leadership that may reshape company strategy and investor confidence in the regenerative medicine firm.
Feb 13
8-K
NRX Pharmaceuticals, Inc. -- 8-K Filing
NRX Pharmaceuticals' board gained a director with healthcare IT expertise through SureTest, Inc., potentially strengthening governance in clinical technology and automation sectors.
Feb 2
Data updated apr 26, 2026 3:47pm
· Source: massive.com